1. [1986. Pert CB](https://www.ncbi.nlm.nih.gov/pubmed/3097649), Hill JM, Ruff MR et al. Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc Natl Acad Sci U S A; 83, 9254-8.
2. [1987. Ruff MR](https://www.ncbi.nlm.nih.gov/pubmed/2888984), Hallberg PL, Hill JM, Pert CB. Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attachment [letter]. Lancet; 2, 751.
3. [1987. Barrera CM](https://www.ncbi.nlm.nih.gov/pubmed/3440215), Kastin AJ, Banks WA. D-[Ala1]-peptide T-amide is transported from blood to brain by a saturable system. Brain Res Bull; 19, 629-633.
4. [1987. Ruff MR](https://www.ncbi.nlm.nih.gov/pubmed/3026840), Martin BM, Ginns EI, Farrar WL, Pert CB. CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis. Relationship to vasoactive intestinal polypeptide. FEBS Lett; 211, 17-22.
5. [1987. Sacerdote P](https://www.ncbi.nlm.nih.gov/pubmed/3682024), Ruff MR, Pert CB. Vasoactive intestinal peptide 1-12: a ligand for the CD4 (T4)/human immunodeficiency virus receptor. J Neurosci Res; 18, 102-107.
6. [Brenneman, 1988](http://onlinelibrary.wiley.com/doi/10.1002/ddr.430150403/abstract). Brenneman DE, Buzy JM, Ruff MR, Pert CB. Peptide T sequences prevent neuronal cell death produced by the envelope protein (gp120) of the human immunodeficiency virus. Drug Devel Res; 15, 361-369.
7. [1988. Moore TC](https://www.ncbi.nlm.nih.gov/pubmed/3267011), Spruck CH, Said SI. In vivo depression of lymphocyte traffic in sheep by VIP and HIV (AIDS)-related peptides. Immunopharmacology; 16, 181-189.
8. [1988. Pert CB](https://www.ncbi.nlm.nih.gov/pubmed/2831805), Ruff MR, Hill JM. AIDS as a neuropeptide disorder: peptide T, VIP, and the HIV receptor. Psychopharmacol Bull; 24, 315-319.
9. 1988. Smith CC, Hallberg PL, Sacerdote P et al. Tritiated Dala1-peptide T binding: A pharmacologic basis for the design of drugs which inhibit HIV receptor binding. Drug Devel Res; 15, 371-379.
10. [1989. Buzy JM](https://www.ncbi.nlm.nih.gov/pubmed/2549792), Brenneman DE, Siegal FP, Ruff MR, Pert CB. Cerebrospinal fluid from cognitively impaired patient with acquired immunodeficiency syndrome shows gp120-like neuronal killing in vitro. Am J Med; 87, 361-362.
11. [1989. Marastoni](https://www.ncbi.nlm.nih.gov/pubmed/2818682) M, Salvadori S, Balboni G et al. Structure-activity relationships of peptide T-related pentapeptides. Arzneimittelforschung; 39, 926-928.
12. [1989. Motta A](https://www.ncbi.nlm.nih.gov/pubmed/2720120), Picone D, Temussi PA, Marastoni M, Tomatis R. Conformational analysis of peptide T and of its C-pentapeptide fragment. Biopolymers; 28, 479-486.
13. [1990. Cotelle N](https://www.ncbi.nlm.nih.gov/pubmed/2119576), Lohez M, Cotelle P, Henichart JP. Conformational study of the threonine-rich C-terminal pentapeptide of peptide T. Biochem Biophys Res Commun; 171, 596-602.
14. [1990. Marastoni M](https://www.ncbi.nlm.nih.gov/pubmed/2323889), Salvadori S, Balboni G et al. Synthesis, metabolic stability and chemotactic activity of peptide T and its analogues. Int J Pept Protein Res; 35, 81-8.
15. [1991. Kahns AH, Bundgaard](http://www.sciencedirect.com/science/article/pii/0378517391903025) H. Facile a-chymotrypsin-catalyzed degradation of the HIV inhibitor [D-Ala1]-Peptide T amide. Int J Pharmaceutics; 77, 65-70.
16. [1992. Urge](https://www.ncbi.nlm.nih.gov/pubmed/1575731) L, Gorbics L, Otvos L. Chemical glycosylation of peptide T at natural and artificial glycosylation sites stabilizes or rearranges the dominant reverse turn structure. Biochem Biophys Res Commun; 184, 1125-1132.
17. [1992. Buzy J](https://www.ncbi.nlm.nih.gov/pubmed/1486472), Brenneman DE, Pert CB, Martin A, Salazar A, Ruff MR. Potent gp120-like neurotoxic activity in the cerebrospinal fluid of HIV-infected individuals is blocked by peptide T. Brain Res; 598, 10-18.
18. [1993. Hill JM](https://www.ncbi.nlm.nih.gov/pubmed/8461978), Mervis RF, Avidor R, Moody TW, Brenneman DE. HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res; 603, 222-233.
19. [1993. Marastoni M](https://www.ncbi.nlm.nih.gov/pubmed/8320038), Salvadori S, Balboni G et al. Structure-activity relationships of cyclic and linear peptide T analogues. Int J Pept Protein Res; 41, 447-454.
20. 1994. Marastoni M, Salvadori S, Scaranari V et al. Synthesis and activity of new linear and cyclic peptide T derivatives. Arzneimittelforschung; 44, 1073-1076.
21. [1994. Marastoni M](https://www.ncbi.nlm.nih.gov/pubmed/7945547), Spisani S, Tomatis R. Synthesis and biological activity of D-glucopyranosyl peptide T derivatives. Arzneimittelforschung; 44, 984-987.
22. [1994. Pozo D, Segura](https://www.ncbi.nlm.nih.gov/pubmed/%20%20%20%207772718) JJ, Guerrero JM, Calvo JR. Peptide T from human immunodeficiency virus does not interact with VIP receptor-effector system in immunocompetent cells of rat and mouse. Biosci Rep; 14, 251-257.
23. [1995. Marastoni M](https://www.ncbi.nlm.nih.gov/pubmed/7575755), Scaranari V, Fantini F, Sevignani C, Tomatis R. Effects of peptide T derivatives on the proliferation of cultured human keratinocytes. Arzneimittelforschung; 45, 891-893.
24. [1995. Phipps DJ](https://www.ncbi.nlm.nih.gov/pubmed/753972), Reed\_Doob P, MacFadden DK, Piovesan JP, Mills GB, Branch DR. An octapeptide analogue of HIV gp120 modulates protein tyrosine kinase activity in activated peripheral blood T lymphocytes. Clin Exp Immunol; 100, 412-418.
25. [1995. Prammer KV](https://www.ncbi.nlm.nih.gov/pubmed/9346835), Otvos L. Structural effects of glycosylation on the C-terminal pentapeptide of peptide T. Biomed Pept Proteins Nucleic Acids; 1, 221-226.
26. [1995. Su SF](https://www.ncbi.nlm.nih.gov/pubmed/%20%20%20%207654767), Amidon GL. Investigation into the intestinal metabolism of [D-Ala1] peptide T amide: implication for oral drug delivery. Biochim Biophys Acta; 1245, 62-68.
27. [1995. Wang L](https://www.ncbi.nlm.nih.gov/pubmed/7727353), Hilliges M, Talme T, Marcusson JA, Wetterberg L, Johansson O. Rearrangement of S-100 immunoreactive Langerhans’ cells in human psoriatic skin treated with peptide T. J Dermatol Sci; 9, 20-26.
28. [1996. Phipps DJ](https://www.ncbi.nlm.nih.gov/pubmed/8828750), MacFadden DK. Inhibition of tumour necrosis factor-alpha explains inhibition of HIV replication by peptide T. AIDS; 10, 919-920.
29. [1996. Socci DJ](https://www.ncbi.nlm.nih.gov/pubmed/8844774), Pert CB, Ruff MR, Arendash GW. Peptide T prevents NBM lesion-induced cortical atrophy in aged rats. Peptides; 17, 831-837.
30. [1996. Wilce JA](https://www.ncbi.nlm.nih.gov/pubmed/9346828), Otvos L, Craik DJ. 1H NMR studies of the effects of glycosylation on the C-terminal pentapeptide of peptide T. Biomed Pept Proteins Nucleic Acids; 2, 59-66.
31. [1998. Liapi C](https://www.ncbi.nlm.nih.gov/pubmed/9540970), Takahashi N, Raynaud F, Evain-Brion D, Anderson WB. Effects of [D-Ala1] peptide T-NH2 and HIV envelope glycoprotein gp120 on cyclic AMP dependent protein kinases in normal and psoriatic human fibroblasts. J Invest Dermatol; 110, 332-337.
32. [1998. Marastoni M](https://www.ncbi.nlm.nih.gov/pubmed/9825124), Spisani S, Tomatis R. Synthesis and biological activity of chelator-peptide T conjugates. Arzneimittelforschung; 48, 1039-1042.
33. [1998. Mulroney SE](https://www.ncbi.nlm.nih.gov/pubmed/9465119), McDonnell KJ, Pert CB et al. HIV gp120 inhibits the somatotropic axis: a possible GH-releasing hormone receptor mechanism for the pathogenesis of AIDS wasting. Proc Natl Acad Sci U S A; 95, 1927-1932.
34. [1998. Raychaudhuri SK](https://www.ncbi.nlm.nih.gov/pubmed/9848397), Raychaudhuri SP, Farber EMP. Anti-chemotactic activities of peptide-T: a possible mechanism of actions for its therapeutic effects on psoriasis. Int J Immunopharmacol; 20, 661-667.
35. [1999. Brenneman DE](https://www.ncbi.nlm.nih.gov/pubmed/10446313), Hauser J, Spong CY, Phillips TM, Pert CB, Ruff M. VIP and D-ala-peptide T-amide release chemokines which prevent HIV-1 GP120-induced neuronal death. Brain Res; 838, 27-36.
36. [1999. Redwine LS](https://www.ncbi.nlm.nih.gov/pubmed/10527688), Pert CB, Rone JD et al. Peptide T blocks GP120/CCR5 chemokine receptor-mediated chemotaxis. Clin Immunol; 93, 124-131.1991. Kahns AH, Bundgaard H. Facile a-chymotrypsin-catalyzed degradation of the HIV inhibitor [D-Ala1]-Peptide T amide. Int J Pharmaceutics; 77, 65-70.
37. [1999. Raychaudhuri SP](https://www.ncbi.nlm.nih.gov/pubmed/10501630), Farber EM, Raychaudhuri SK. Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines. Int J Immunopharmacol; 21, 609-15.
38. [2000. Boschi A](https://www.ncbi.nlm.nih.gov/pubmed/11150712), Uccelli L, Bolzati C et al. A CD(4)/T(4) receptor peptide ligand labeled with technetium-99m: synthesis and biological activity. Nucl Med Biol; 27, 791-795.
39. [2000. Manfredini S](https://www.ncbi.nlm.nih.gov/pubmed/10732970), Marastoni-M, Tomatis R et al. Peptide T-araC conjugates: solid-phase synthesis and biological activity of N4-(acylpeptidyl)-araC. Bioorg Med Chem; 8, 539-547.
40. [2000. Saez-Torres I](https://www.ncbi.nlm.nih.gov/pubmed/10886253), Espejo C, Perez JJ, Acarin N, Montalban X, Martinez-Caceres EM. Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats. Clin Exp Immunol; 121, 151-156.
41. [2001. Bagger MA](https://www.ncbi.nlm.nih.gov/pubmed/11457652), Nielsen HW. Nasal bioavailability of peptide T in rabbits: absorption enhancement by sodium glycocholate and glycofurol. Eur J Pharm Sci; 14, 69-74.
42. [2001. Picone D, Rivieccio](https://www.ncbi.nlm.nih.gov/pubmed/%20%20%20%2011354463) A, Crescenzi O et al. Peptide T revisited: conformational mimicry of epitopes of anti-HIV proteins. J Pept Sci; 7, 197-207.
43. [2001. Ruff MR](https://www.ncbi.nlm.nih.gov/pubmed/%20%20%20%2011530189), Melendez-Guerrero LM, Yang QE et al. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res; 52, 63-75.
44. [2002. Tufano MA](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12366410), Greco R, Paoletti I, Donnarumma G, Canozo N, Baroni A. Immunomodulatory effects of peptide T on human keratinocyte cells. Br J Dermatol; 147, 663-669.
45. [2003. Polianova MT](https://www.ncbi.nlm.nih.gov/pubmed/14499289), Ruscetti FW, Pert CB et al. Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA). Peptides; 24, 1093-1098.
46. [2003. Ruff MR](https://www.ncbi.nlm.nih.gov/pubmed/15043212), Polianova M, Yang QE, Leoung GS, Ruscetti FW, Pert CB. Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Curr HIV Res; 1, 51-67.
47. [2005. Baroni A, Paoletti](https://www.ncbi.nlm.nih.gov/pubmed/16232308) I, Greco R et al. Immunomodulatory effects of a set of amygdalin analogues on human keratinocyte cells. Exp Dermatol; 14, 854-859.
48. 2005. Polianova MT, Ruscetti FW, Pert CB, Ruff MR. Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA). Antiviral Res; 67, 83-92.
49. [2005. Rosi S,](https://www.ncbi.nlm.nih.gov/pubmed/15979806) Pert CB, Ruff MR, McGann-Gramling K, Wenk GL. Chemokine receptor 5 antagonist D-Ala-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer’s disease. Neuroscience; 134, 671-676.
50. [Polianova, 2005](https://www.ncbi.nlm.nih.gov/pubmed/16002156) Polianova, M. T., F. W. Ruscetti, C. B. Pert, and M. R. Ruff. 2005. Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA). Antiviral Res 67: 83-92.
51. [2007. Pollicita M](https://www.ncbi.nlm.nih.gov/pubmed/18046961), Ruff MR, Pert CB et al. Profound anti-HIV-1 activity of DAPTA in monocytes/macrophages and inhibition of CCR5-mediated apoptosis in neuronal cells. Antivir Chem Chemother; 18, 285-295.
52. [2009. Bachis A](https://www.ncbi.nlm.nih.gov/pubmed/%20%20%20%2019034668), Biggio F, Major EO, Mocchetti I. M- and T-tropic HIVs promote apoptosis in rat neurons. J Neuroimmune Pharmacol; 4, 150-160.
53. [2009 Passos](http://www.sciencedirect.com/science/article/pii/S0002944010606700), G.F., C.P. Figueiredo, R.D. Prediger, P. Pandolfo, F.S. Duarte, R. Medeiros, and J.B. Calixto. 2009. Role of the macrophage inflammatory protein-1alpha/CC chemokine receptor 5 signaling pathway in the neuroinflammatory response and cognitive deficits induced by beta-amyloid peptide. *Am J Pathol*. 175:1586-1597.
54. [2012. Di Prisco S](https://www.ncbi.nlm.nih.gov/pubmed/22385043), Summa M, Chellakudam V, Rossi PI, Pittaluga A. RANTES-mediated control of excitatory amino acid release in mouse spinal cord. J Neurochem; 121, 428-437.
55. [2012. Padi SS](https://www.ncbi.nlm.nih.gov/pubmed/22033364), Shi XQ, Zhao YQ et al. Attenuation of rodent neuropathic pain by an orally active peptide, RAP-103, which potently blocks CCR2- and CCR5-mediated monocyte chemotaxis and inflammation. Pain; 153, 95-106.
56. [2012. Saika F](https://www.ncbi.nlm.nih.gov/pubmed/22528550), Kiguchi N, Kobayashi Y, Fukazawa Y, Kishioka S. CC-chemokine ligand 4/macrophage inflammatory protein-1beta participates in the induction of neuropathic pain after peripheral nerve injury. Eur J Pain; 16, 1271-1280.
57. [2013. Lee YK, Choi](https://www.ncbi.nlm.nih.gov/pubmed/23147416) DY, Jung YY et al. Decreased pain responses of C-C chemokine receptor 5 knockout mice to chemical or inflammatory stimuli. Neuropharmacology; 67, 57-65.
58. [2013. Paoletti I](https://www.ncbi.nlm.nih.gov/pubmed/23933845), De Gregorio V, Baroni A, Tufano MA, Donnarumma G, Perez JJ. Amygdalin analogues inhibit IFN-gamma signalling and reduce the inflammatory response in human epidermal keratinocytes. Inflammation; 36, 1316-1326.
59. [2014. Luehmann HP](https://www.ncbi.nlm.nih.gov/pubmed/24591489), Pressly ED, Detering L et al. PET/CT imaging of chemokine receptor CCR5 in vascular injury model using targeted nanoparticle. J Nucl Med; 55, 629-634.
60. [2014. Pevida M](https://www.ncbi.nlm.nih.gov/pubmed/24316469), Lastra A, Meana A, Hidalgo A, Baamonde A, Menendez L. The chemokine CCL5 induces CCR1-mediated hyperalgesia in mice inoculated with NCTC 2472 tumoral cells. Neuroscience; 259, 113-125.
61. [2015. Wei,L](http://jnm.snmjournals.org/content/56/supplement_3/1076)., J. Petryk, M. Kamkar, C. Gaudet, W. Gan, Y. Duan, and T. Ruddy. 2015. I-123 labeled DAPTA peptide targeting chemokine receptor CCR5 as a potential inflammation imaging agent. *Journal of Nuclear Medicine* 56: 1076
62. [2017. Hang LH, Li SN,](https://www.ncbi.nlm.nih.gov/pubmed/27848062) Dan X, Shu WW, Luo H, Shao DH. Involvement of Spinal CCR5/PKCγ Signaling Pathway in the Maintenance of Cancer-Induced Bone Pain. Neurochem Res;42(2):563-571
63. [2016. Hwang CJ](https://www.ncbi.nlm.nih.gov/pubmed/26910914), Park MH, Hwang JY et al. CCR5 deficiency accelerates lipopolysaccharide-induced astrogliosis, amyloid-beta deposit and impaired memory function. Oncotarget; 7, 11984-11999.
64. [2016. Li L](https://www.ncbi.nlm.nih.gov/pubmed/26983670), Zhi D, Shen Y, Liu K, Li H, Chen J. Effects of CC-chemokine receptor 5 on ROCK2 and P-MLC2 expression after focal cerebral ischaemia-reperfusion injury in rats. Brain Inj; 30, 468-473.
65. [2017. González-Rodríguez S](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=28126501), Álvarez MG, García-Domínguez M et al. Hyperalgesic and hypoalgesic mechanisms evoked by the acute administration of CCL5 in mice. Brain Behav Immun; 62:151-161
66. [2017 Ruff, MR](http://www.medcraveonline.com/JMEN/JMEN-05-00143.pdf)  Virobiome derived Peptide T:Anti-inflammatory peptides for treating neuro-AIDS and neurodegenerative diseases JMEM 5(2)
67. [2017. Lu, Y. et al.,](https://www.ncbi.nlm.nih.gov/pubmed/29037608) . Chemokine CCL8 and its receptor CCR5 in the spinal cord are involved in visceral pain induced by experimental colitis in mice. *Brain Res Bull*. 135:170-178.
68. [2018 Noda, M., et al.](https://www.ncbi.nlm.nih.gov/pubmed/29248693), Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8. Neurochem Int, 2018.
69. [2018 Garcia-Dominguez, M., et al](https://www.ncbi.nlm.nih.gov/pubmed/29907903)., The Chemokine CCL4 (MIP-1beta) Evokes Antinociceptive Effects in Mice: a Role for CD4(+) Lymphocytes and Met-Enkephalin. Mol Neurobiol, 2018.